{"sent_idx": "7", "frame_idx": "1", "ev": "In a per protocol analysis after 6 months, L3 bone mineral density has increased statistically significantly in the vitamin K group compared to the control group (0.01 \u00b1 0.03 g/cm2 vs -0.008 \u00b1 0.04 g/cm2, P = 0.049).", "icos": [["0.9991441", "vitamin K", "Vitamin K", "L3 bone mineral density"], ["0.9991441", "vitamin K", "vitamin K", "L3 bone mineral density"], ["0.9989673", "vitamin K", "vitamin K2", "L3 bone mineral density"], ["0.99892825", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "L3 bone mineral density"], ["0.99611473", "vitamin K", "vitamin K supplement", "L3 bone mineral density"]], "sample": "c"}
{"sent_idx": "8", "frame_idx": "2", "ev": "UcOC concentration was also significantly decreased in the vitamin K group (-1.6 \u00b1 1.6 ng/dL vs -0.4 \u00b1 1.1 ng/dL, P = 0.008).", "icos": [["0.99872214", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "UcOC concentration"], ["0.9966", "vitamin K", "Anti - osteocalcin ( OC ) antibody", "UcOC concentration"], ["0.9959156", "vitamin K", "vitamin K1 supplementation", "UcOC concentration"], ["0.9953434", "vitamin K", "vitamin K supplementation", "UcOC concentration"], ["0.9953434", "vitamin K", "Vitamin K supplementation", "UcOC concentration"]], "sample": "c"}
{"sent_idx": "51", "frame_idx": "3", "ev": "In the ITT analysis comparing the characteristics of the vitamin K group with the control group (Table 1), the age at menopause in the vitamin K group (49.6 \u00b1 2.7 yr) was significantly different from the age at menopause in the control group (50.8 \u00b1 1.7 yr, P = 0.03).", "icos": [["0.99945694", "vitamin K", "Vitamin K", "age at menopause"], ["0.99945694", "vitamin K", "vitamin K", "age at menopause"], ["0.9992262", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "age at menopause"], ["0.99910307", "vitamin K", "vitamin K2", "age at menopause"], ["0.99606687", "vitamin K", "vitamin K supplement", "age at menopause"]], "sample": "c"}
{"sent_idx": "55", "frame_idx": "5", "ev": "BMDs in lumbar and femur were similar in both the vitamin K and the control groups.", "icos": [["0.9982659", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "BMDs in lumbar and femur"], ["0.9977465", "vitamin K", "solid - phase anti - Glu 21 , 24 - OC antibody", "BMDs in lumbar and femur"], ["0.9975688", "vitamin K", "Anti - osteocalcin ( OC ) antibody", "BMDs in lumbar and femur"], ["0.99621826", "vitamin K", "Vitamin K", "BMDs in lumbar and femur"], ["0.99621826", "vitamin K", "vitamin K", "BMDs in lumbar and femur"]], "sample": "c"}
{"sent_idx": "56", "frame_idx": "6", "ev": "In addition, the UcOC concentration in the vitamin K group (2.1 \u00b1 1.7 ng/dL) was not significantly different from that in the control group (1.5 \u00b1 1.0 ng/dL, P = 0.214).", "icos": [["0.9967649", "vitamin K", "Vitamin K", "UcOC concentration"], ["0.9967649", "vitamin K", "vitamin K", "UcOC concentration"], ["0.9960979", "vitamin K", "Anti - osteocalcin ( OC ) antibody", "UcOC concentration"], ["0.99595463", "vitamin K", "vitamin K2", "UcOC concentration"], ["0.99357504", "vitamin K", "vitamin K or UcOC", "UcOC concentration"]], "sample": "c"}
{"sent_idx": "58", "frame_idx": "7", "ev": "There were no significant differences in blood urea nitrogen, creatinine, calcium and serum bone-specific alkaline phosphatase (BSALP) between the vitamin K and the control groups.", "icos": [["0.9979012", "vitamin K", "Vitamin K", "blood urea nitrogen , creatinine , calcium and serum bone - specific alkaline phosphatase ( BSALP )"], ["0.9979012", "vitamin K", "vitamin K", "blood urea nitrogen , creatinine , calcium and serum bone - specific alkaline phosphatase ( BSALP )"], ["0.9974124", "vitamin K", "vitamin K supplementation with vitamin D and calcium", "blood urea nitrogen , creatinine , calcium and serum bone - specific alkaline phosphatase ( BSALP )"], ["0.9973564", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "blood urea nitrogen , creatinine , calcium and serum bone - specific alkaline phosphatase ( BSALP )"], ["0.9967596", "vitamin K", "vitamin K supplementation to vitamin D and calcium", "blood urea nitrogen , creatinine , calcium and serum bone - specific alkaline phosphatase ( BSALP )"]], "sample": "c"}
{"sent_idx": "59", "frame_idx": "8", "ev": "The BMD in L1-L4 and femur neck, and in the ward in the vitamin K group were not different from those in the control group.", "icos": [["0.9981862", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "BMD in L1 - L4 and femur neck"], ["0.9977093", "vitamin K", "Vitamin K", "BMD in L1 - L4 and femur neck"], ["0.9977093", "vitamin K", "vitamin K", "BMD in L1 - L4 and femur neck"], ["0.9962604", "vitamin K", "vitamin K2", "BMD in L1 - L4 and femur neck"], ["0.98827374", "vitamin K", "vitamin K , vitamin D and calcium", "BMD in L1 - L4 and femur neck"]], "sample": "c"}
{"sent_idx": "60", "frame_idx": "9", "ev": "The serum UcOC level in the vitamin K group (2.1 \u00b1 1.7 ng/dL) was higher than that in the control group (1.5 \u00b1 1.0 ng/dL), but showed no significant difference (P = 0.21).", "icos": [["0.99810684", "vitamin K", "Vitamin K", "serum UcOC level"], ["0.99810684", "vitamin K", "vitamin K", "serum UcOC level"], ["0.9950369", "vitamin K", "vitamin K2", "serum UcOC level"], ["0.9915677", "vitamin K", "Anti - osteocalcin ( OC ) antibody", "serum UcOC level"], ["0.98884344", "vitamin K", "control group ( vitamin D + calcium supplement )", "serum UcOC level"]], "sample": "c"}
{"sent_idx": "61", "frame_idx": "10", "ev": "Osteocalcin level was nonsignificantly lower in the vitamin K group (9.6 \u00b1 6.4 ng/dL) than in the control group (11.7 \u00b1 6.4 ng/dL, P = 0.29).", "icos": [["0.99857676", "vitamin K", "Vitamin K", "Osteocalcin level"], ["0.99857676", "vitamin K", "vitamin K", "Osteocalcin level"], ["0.9968521", "vitamin K", "vitamin K2", "Osteocalcin level"], ["0.9956227", "vitamin K", "Anti - osteocalcin ( OC ) antibody", "Osteocalcin level"], ["0.99489176", "vitamin K", "control group ( vitamin D + calcium supplement )", "Osteocalcin level"]], "sample": "c"}
{"sent_idx": "62", "frame_idx": "11", "ev": "The BSALP level was 189.5 \u00b1 64.5 \u03bcg/L in the vitamin K group and 185.6 \u00b1 46.0 \u03bcg/L in the control group (P = 0.827).", "icos": [["0.9983512", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "BSALP level"], ["0.99639684", "vitamin K", "vitamin K supplementation", "BSALP level"], ["0.99639684", "vitamin K", "Vitamin K supplementation", "BSALP level"], ["0.99536884", "vitamin K", "Vitamin K", "BSALP level"], ["0.99536884", "vitamin K", "vitamin K", "BSALP level"]], "sample": "c"}
{"sent_idx": "63", "frame_idx": "12", "ev": "No significant differences in BMD and biomarker values between the vitamin K and the control groups indicated that the randomization worked well.", "icos": [["0.9966401", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "BMD and biomarker values"], ["0.9894812", "vitamin K", "Vitamin K", "BMD and biomarker values"], ["0.9894812", "vitamin K", "vitamin K", "BMD and biomarker values"], ["0.90104014", "vitamin K", "control group ( vitamin D + calcium supplement )", "BMD and biomarker values"], ["0.86343414", "vitamin K", "vitamin K supplement", "BMD and biomarker values"]], "sample": "c"}
{"sent_idx": "65", "frame_idx": "13", "ev": "After 6 months of treatment, the L3 BMD in the vitamin K group compared to the control group increased statistically significantly (0.01 \u00b1 0.03 g/cm2 vs -0.008 \u00b1 0.04 g/cm2, P = 0.049).", "icos": [["0.99489", "vitamin K", "Vitamin K", "L3 BMD"], ["0.99489", "vitamin K", "vitamin K", "L3 BMD"], ["0.9869631", "vitamin K", "Anti - osteocalcin ( OC ) antibody", "L3 BMD"], ["0.9797721", "vitamin K", "control group ( vitamin D + calcium supplement )", "L3 BMD"], ["0.9733488", "vitamin K", "vitamin K2", "L3 BMD"]], "sample": "c"}
{"sent_idx": "66", "frame_idx": "14", "ev": "Compared to BMD at baseline, BMD in femur at month 6 was significantly increased in both the vitamin K and the control groups.", "icos": [["0.9977487", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "BMD in femur"], ["0.9963482", "vitamin K", "Anti - osteocalcin ( OC ) antibody", "BMD in femur"], ["0.9952335", "vitamin K", "IU of vitamin D once a day , and 315 mg of calcium twice daily )", "BMD in femur"], ["0.9924408", "vitamin K", "Vitamin K", "BMD in femur"], ["0.9924408", "vitamin K", "vitamin K", "BMD in femur"]], "sample": "c"}
{"sent_idx": "66", "frame_idx": "15", "ev": "Compared to BMD at baseline, BMD in femur at month 6 was significantly increased in both the vitamin K and the control groups.", "icos": [["0.9967854", "vitamin K", "Anti - osteocalcin ( OC ) antibody", "BMD"], ["0.9950224", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "BMD"], ["0.9927973", "vitamin K", "IU of vitamin D once a day , and 315 mg of calcium twice daily )", "BMD"], ["0.98853534", "vitamin K", "vitamin K supplementation", "BMD"], ["0.98853534", "vitamin K", "Vitamin K supplementation", "BMD"]], "sample": "c"}
{"sent_idx": "67", "frame_idx": "16", "ev": "However, after 6 months of treatment, BMD in the vitamin K group was not statistically different from BMD in the control group.", "icos": [["0.9973099", "vitamin K", "Vitamin K", "BMD"], ["0.9973099", "vitamin K", "vitamin K", "BMD"], ["0.9969375", "vitamin K", "Anti - osteocalcin ( OC ) antibody", "BMD"], ["0.99549496", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "BMD"], ["0.9952905", "vitamin K", "control group ( vitamin D + calcium supplement )", "BMD"]], "sample": "c"}
{"sent_idx": "68", "frame_idx": "17", "ev": "In addition, compared to the baseline, the vitamin K group significantly decreased UcOC concentration (-1.6 \u00b1 1.6 ng/dL, P < 0.01), whereas the UcOC level in the control group did not change (-0.4 \u00b1 1.1 ng/dL).", "icos": [["0.9992962", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "UcOC concentration"], ["0.99906975", "vitamin K", "Vitamin K", "UcOC concentration"], ["0.99906975", "vitamin K", "vitamin K", "UcOC concentration"], ["0.99716115", "vitamin K", "vitamin K supplement", "UcOC concentration"], ["0.9962251", "vitamin K", "vitamin K supplementation", "UcOC concentration"]], "sample": "c"}
{"sent_idx": "68", "frame_idx": "18", "ev": "In addition, compared to the baseline, the vitamin K group significantly decreased UcOC concentration (-1.6 \u00b1 1.6 ng/dL, P < 0.01), whereas the UcOC level in the control group did not change (-0.4 \u00b1 1.1 ng/dL).", "icos": [["0.9992817", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "UcOC level"], ["0.9988237", "vitamin K", "Vitamin K", "UcOC level"], ["0.9988237", "vitamin K", "vitamin K", "UcOC level"], ["0.9964347", "vitamin K", "vitamin K supplement", "UcOC level"], ["0.9962962", "vitamin K", "vitamin K supplementation", "UcOC level"]], "sample": "c"}
{"sent_idx": "71", "frame_idx": "19", "ev": "Triglyceride level decreased in the vitamin K group (-10.0 \u00b1 59.1 ng/dL) (Table 3).", "icos": [["0.9994468", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "Triglyceride level"], ["0.9991636", "vitamin K", "Vitamin K", "Triglyceride level"], ["0.9991636", "vitamin K", "vitamin K", "Triglyceride level"], ["0.9979511", "vitamin K", "vitamin K supplementation", "Triglyceride level"], ["0.9979511", "vitamin K", "Vitamin K supplementation", "Triglyceride level"]], "sample": "c"}
{"sent_idx": "72", "frame_idx": "20", "ev": "Three people complained of nausea sensation twice after taking vitamin K. No other participants including people in the control group reported adverse events during the study period.", "icos": [["0.9995561", "vitamin K", "Vitamin K", "adverse events"], ["0.9995561", "vitamin K", "vitamin K", "adverse events"], ["0.99948347", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "adverse events"], ["0.9992561", "vitamin K", "vitamin K2", "adverse events"], ["0.9991273", "vitamin K", "vitamin K supplement", "adverse events"]], "sample": "c"}
{"sent_idx": "72", "frame_idx": "21", "ev": "Three people complained of nausea sensation twice after taking vitamin K. No other participants including people in the control group reported adverse events during the study period.", "icos": [["0.99958044", "vitamin K", "Vitamin K", "nausea sensation"], ["0.99958044", "vitamin K", "vitamin K", "nausea sensation"], ["0.9994968", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "nausea sensation"], ["0.9994746", "vitamin K", "vitamin K2", "nausea sensation"], ["0.9992066", "vitamin K", "vitamin K + vitamin D + calcium", "nausea sensation"]], "sample": "c"}
{"sent_idx": "75", "frame_idx": "22", "ev": "Compared to the control group, the vitamin K group significantly decreased serum UcOC concentration (P = 0.008).", "icos": [["0.9989888", "vitamin K", "Vitamin K", "serum UcOC concentration"], ["0.9989888", "vitamin K", "vitamin K", "serum UcOC concentration"], ["0.99494725", "vitamin K", "vitamin K2", "serum UcOC concentration"], ["0.99446267", "vitamin K", "Anti - osteocalcin ( OC ) antibody", "serum UcOC concentration"], ["0.9880436", "vitamin K", "vitamin K supplement", "serum UcOC concentration"]], "sample": "c"}
{"sent_idx": "76", "frame_idx": "23", "ev": "Osteocalcin level was higher in the vitamin K group than in the control group, but the difference was not significant (P = 0.14).", "icos": [["0.99948716", "vitamin K", "Vitamin K", "Osteocalcin level"], ["0.99948716", "vitamin K", "vitamin K", "Osteocalcin level"], ["0.99909794", "vitamin K", "vitamin K2", "Osteocalcin level"], ["0.99901736", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "Osteocalcin level"], ["0.9966383", "vitamin K", "vitamin K supplement", "Osteocalcin level"]], "sample": "c"}
{"sent_idx": "79", "frame_idx": "24", "ev": "The UcOC concentration significantly decreased in the vitamin K group compared to the control group (P < 0.01), and the osteocalcin level increased nonsignificantly in the vitamin K group (P = 0.14).", "icos": [["0.9993826", "vitamin K", "Vitamin K", "osteocalcin level"], ["0.9993826", "vitamin K", "vitamin K", "osteocalcin level"], ["0.9976411", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "osteocalcin level"], ["0.9972926", "vitamin K", "vitamin K2", "osteocalcin level"], ["0.994062", "vitamin K", "vitamin K or UcOC", "osteocalcin level"]], "sample": "c"}
{"sent_idx": "79", "frame_idx": "25", "ev": "The UcOC concentration significantly decreased in the vitamin K group compared to the control group (P < 0.01), and the osteocalcin level increased nonsignificantly in the vitamin K group (P = 0.14).", "icos": [["0.9991394", "vitamin K", "Vitamin K", "UcOC concentration"], ["0.9991394", "vitamin K", "vitamin K", "UcOC concentration"], ["0.99525094", "vitamin K", "vitamin K2", "UcOC concentration"], ["0.99401397", "vitamin K", "Anti - osteocalcin ( OC ) antibody", "UcOC concentration"], ["0.9925783", "vitamin K", "vitamin K or UcOC", "UcOC concentration"]], "sample": "c"}
{"sent_idx": "80", "frame_idx": "26", "ev": "The triglyceride level decreased in the vitamin K group, but was not statistically different from the control group.", "icos": [["0.99942917", "vitamin K", "Vitamin K", "triglyceride level"], ["0.99942917", "vitamin K", "vitamin K", "triglyceride level"], ["0.99861586", "vitamin K", "vitamin K2", "triglyceride level"], ["0.9961784", "vitamin K", "vitamin K supplement", "triglyceride level"], ["0.9956994", "vitamin K", "vitamin K , anti - lipid medications , hormone replacement therapy", "triglyceride level"]], "sample": "c"}
